Alle Fälle anzeigen
ORD 3577/2025
—·EP2493466: NOVEL ANTITUMORAL USE OF CABAZITAXEL
- Verfahrensdetails
- Status—VerfahrensartVerfahrensantragKategorieVerfahrensführungsanordnungen
- Parteien
- Kläger
- Sanofi SA
- Sanofi Winthrop Industrie
- Sanofi-Aventis GmbH
- Sanofi Belgium
- Sanofi-Aventis Deutschland GmbH
- Sanofi S.r.l.
- Sanofi B.V.
- Sanofi - Produtos Farmaceuticos Lda
- Sanofi AB
- Sanofi A/S
Vertreter: Frédéric Chevallier (Herbert Smith Freehills Kramer LLP)Beklagte- Accord Healthcare S.L.U.
- Accord Healthcare GmbH
- Accord Healthcare B.V.
- Accord Healthcare Italia Srl
- Accord Healthcare, Unipessoal Lda.
- Accord Healthcare AB
- STADAPHARM GmbH
- STADA Arzneimittel AG
- STADA Nordic ApS
- Reddy Pharma SAS
- betapharm Arzneimittel GmbH
- Dr Reddy's Srl
- Zentiva France
- Zentiva Pharma GmbH
- Zentiva, k.s.
Vertreter: Jules Fabre (Pinsent Mason); Arjan Reijns (Pinsent Mason); Louise Millot (Pinsent Mason); Daniel Hoppe (Bonabry); Christian Meyer (Maiwald); Anja Lunze (Taylor Wessing); Elisabeth Greiner (df-mp) - Division
- Munich LD
- Richter
- Matthias Zigann · Presiding judge and judge-rapporteur
- Technology
- Pharmaceutical & Medical
- Sprache
- —
- Erste Entscheidung
- 22. Jan. 2025
Entscheidungen
- 2025-01-22Generic Order
The Munich Local Division issued a case-management order following a preliminary interim conference in Sanofi's infringement actions (four separate cases) against multiple generic-drug defendants (Accord, STADA, Dr. Reddy's, Zentiva), setting the value of infringement claims and counterclaims, directing Sanofi to remedy formal deficiencies in its pleadings, and waiving all other outstanding deadlines pending clarification.
Rechtsfragen:Case management following preliminary interim conference under R. 105.5 RoPFormal requirements for statement of claimValuation of infringement claims and counterclaims for revocationAdditional court fees for infringement actions
Dokumente
- 128F90FEC7A0FA65D56094BD1D3D4B0E_en.pdf2025-01-22EN